1  Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, Shan Z, Liu Y, Cai Z, Tong X, Luan Y, Tan X, Luan B, Ge X, Ji H, Jiang

    X, Wang P.  Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11. 2021, 

    Cancer Res. canres.0567.2021. doi: 10.1158/0008-5472.CAN-21-0567

2  Lomphithak T, Akara-Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, Unno M, Cai Z, Sasano H, 

    Jitkaew S. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1

    expression in cholangiocarcinoma. 2021, Sci Rep, 11(1):11743.

3  Baik JY, Liu Z, Jiao D, Kwon HJ, Yan J, Kadigamuwa C, Choe M, Lake R, Kruhlak M, Tandon M, Cai Z, Choksi S, Liu ZG.

    ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer. 2021, Nat Commun, 12(1):2666
4  Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X. BCL6 confers KRAS-mutant non-

    small  cell lung  cancer resistance to BET inhibitors. 2021, J Clin Invest.  131(1):133090. 

5 Rui C, Shi S, Ren W, Qin X, Zhuang C, Chen X, Chen G, Yu J, Wang H, Cai Z. The multitargeted kinase inhibitor 

   KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. 2021, Biochem

   Pharmacol. 2;188:114542.